Autologous TGFbRII-knockout anti-interleukin-13 receptor alpha 2 CAR T cells

{
  "id": "MLC-T-ONC-011775",
  "term": "Autologous TGFbRII-knockout anti-interleukin-13 receptor alpha 2 CAR T cells",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for interleukin-13 receptor alpha 2 (IL13Ra2), and to knock out the expression of transforming growth factor-beta receptor II (TGFbRII), with potential immunostimulating and antineoplastic activities. Upon administration, autologous TGFbRII-KO anti-IL13Ra2 CAR T cells target and bind to IL13Ra2 expressed on the surface of tumor cells. This induces selective toxicity in tumor cells expressing IL13Ra2. IL13Ra2, a cancer-associated receptor, is overexpressed by a variety of tumor cell types including glioblastoma multiforme (GBM); it is associated with increased invasiveness of tumor cells. By knocking out the expression of TGFbRII, the immunosuppressive cytokine TGF-beta is unable to bind to the T-cells and prevent the activation of the T-cells. TGF-beta contributes to the immunosuppressive nature of the tumor microenvironment (TME), and plays a key role in promoting tumor initiation, metastasis, and suppressing anti-tumor immunity.",
  "synonyms": [
    "autologous TGF-betaR2KO/IL13R-alpha2-CAR T cells",
    "autologous TGFbRII-KO anti-IL13Ra2 CAR T cells",
    "autologous TGFbRII-KO anti-IL13Ra2 CAR-T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-tgfbrii-knockout-anti-interleukin-13-receptor-alpha-2-car-t-cells/"
}